From left: V. Strauch, Dr. M. Böttcher, S. Richter, F. Karl, S. Gamali, Dr. R. Böttcher-Loschinski, D. Saul, Prof. Dr. D. Mougiakakos, K. Mentz, J. Saborido, S. Tohumeken, S. Jitschin, Dr. Stoll, K. Panagiotidis, Dr. Jacobs, Dr. Dr. R. Jitschin
Dr. Mirjeta Berisha, physician scientist
Sara Gamali, MTA
Dr. Benedikt Jacobs, physician scientist
Simon Jitschin, MTA
Franziska Karl, PhD student
Dr. Romy Loschinski-Böttcher, postdoc
Kristin Mentz, MTA
Konstantinos Panagiotidis, PhD student
Judith Rial Saborido, PhD student
Domenica Saul, MTA
Dr. Andrej Stoll, MSc, physician scientist
Vivien Strauch, PhD student
Sehmus Tohumeken, PhD student
Our group studies the immune system in cancer and following stem cell transplantation. Tumors can impact immune responses and thereby escape from immune surveillance. A better understanding of the underlying mechanisms shall help us to develop innovative immune-based therapies against cancer. Furthermore, we seek out to utilize our insights from tumor biology for a targeted immunological fine-tuning. Those approaches could represent the foundation for novel experimental interventions against Graft-versus-Host disease that affects transplanted patients and that can be difficult treat.
Metabolic tumor targeting
Regulatory immune cells
We offer numerous opportunities for PhDs and MDs at all levels of their training to join our efforts for improving cancer treatment.
We encourage and support students to apply for scholarships from the Deutsche Krebshilfe, the Deutsche José Carreras Leukämie-Stiftung e.V. and IZKF Erlangen.
If you are interested in becoming a member of our team please contact via E-Mail!
Bruns H, Böttcher M, Qorraj M, Fabri M, Jitschin S, Dindorf J, Busch L, Jitschin R, Mackensen A, Mougiakakos D. CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D, Leukemia 2017, 31(4):985-988.
Qorraj M, Bruns H, Böttcher M, Weigand L, Saul D, Mackensen A, Jitschin R, Mougiakakos D. The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia, Leukemia 2017, 31(2):470-478.
Braun M, Qorraj M, Büttner M, Klein FA, Saul D, Aigner M, Huber W, Mackensen A, Jitschin R, Mougiakakos D. CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR Axis. Leukemia 2016, 30(8):1788-92.
Böttcher M, Hofmann AD, Bruns H, Haibach M, Loschinski R, Saul D, Mackensen A, Le Blanc K, Jitschin R, Mougiakakos D. Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-cell Activation. Stem Cells 2016, 34(2):516-21.
Jitschin R, Braun M, Qorraj M, Saul D, Le Blanc K, Zenz T, Mougiakakos D. Stromal cell-mediated glycolytic switch in CLL-cells involves Notch-c-Myc signaling. Blood 2015, 125(22):3432-6.
Jitschin R, Braun M, Büttner M, Bricks J, Berger J, Eckart MJ, Krause SW, Le Blanc K, Mackensen A, Mougiakakos D. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014, 124(5):750-60.
Jitschin R, Hofmann AD, Bruns H, Gießl A, Bricks J, Berger J, Saul D, Eckart MJ, Mackensen A, Mougiakakos D. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood 2014, 123(17):2663-72.